- FibroBiologics Announces 2024 Annual Meeting of Stockholders
- FibroBiologics Files 2024 First Quarter Report
- FibroBiologics to Present at the BIO International Convention 2024
- FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids
- FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office
- FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA
- FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
More ▼
Key statistics
As of last trade Fibrobiologics Inc (SG0:BER) traded at 10.00, -21.01% below its 52-week high of 12.66, set on Mar 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.10 |
---|---|
High | 10.10 |
Low | 10.00 |
Bid | 9.70 |
Offer | 10.30 |
Previous close | 10.30 |
Average volume | 0.00 |
---|---|
Shares outstanding | 32.72m |
Free float | 22.79m |
P/E (TTM) | -- |
Market cap | 359.91m USD |
EPS (TTM) | -1.03 USD |
Data delayed at least 15 minutes, as of May 21 2024 14:36 BST.
More ▼